Status epilepticus in Auckland, New Zealand: Treatment patterns and determinants of outcome in a prospective population‐based cohort
Objective Determination of the real‐world performance of a health care system in the treatment of status epilepticus (SE). Methods Prospective, multicenter population‐based study of SE in Auckland, New Zealand (NZ) over 1 year, with data recorded in the EpiNet database. Focus on treatment patterns a...
Saved in:
Published in | Epilepsia (Copenhagen) Vol. 65; no. 6; pp. 1605 - 1619 |
---|---|
Main Authors | , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Wiley Subscription Services, Inc
01.06.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Objective
Determination of the real‐world performance of a health care system in the treatment of status epilepticus (SE).
Methods
Prospective, multicenter population‐based study of SE in Auckland, New Zealand (NZ) over 1 year, with data recorded in the EpiNet database. Focus on treatment patterns and determinants of SE duration and 30‐day mortality. The incidence, etiology, ethnic discrepancies, and seizure characteristics of this cohort have been published previously.
Results
A total of 365 patients were included in this treatment cohort; 326 patients (89.3%) were brought to hospital because of SE, whereas 39 patients (10.7%) developed SE during a hospital admission for another reason. Overall, 190 (52.1%) had a known history of epilepsy and 254 (70.0%) presented with SE with prominent motor activity. The mean Status Epilepticus Severity Score (STESS) was 2.15 and the mean SE duration of all patients was 44 min. SE self‐terminated without any treatment in 84 patients (22.7%). Earlier administration of appropriately dosed benzodiazepine in the pre‐hospital setting was a major determinant of SE duration. Univariate analysis demonstrated that mortality was significantly higher in older patients, patients with longer durations of SE, higher STESS, and patients who developed SE in hospital, but these did not maintain significance with multivariate analysis. There was no difference in the performance of the health care system in the treatment of SE across ethnic groups.
Significance
When SE was defined as 10 continuous minutes of seizure, overall mortality was lower than expected and many patients had self‐limited presentations for which no treatment was required. Although there were disparities in the incidence of SE across ethnic groups there was no difference in treatment or outcome. The finding highlights the benefit of a health care system designed to deliver universal health care. |
---|---|
AbstractList | Objective
Determination of the real‐world performance of a health care system in the treatment of status epilepticus (SE).
Methods
Prospective, multicenter population‐based study of SE in Auckland, New Zealand (NZ) over 1 year, with data recorded in the EpiNet database. Focus on treatment patterns and determinants of SE duration and 30‐day mortality. The incidence, etiology, ethnic discrepancies, and seizure characteristics of this cohort have been published previously.
Results
A total of 365 patients were included in this treatment cohort; 326 patients (89.3%) were brought to hospital because of SE, whereas 39 patients (10.7%) developed SE during a hospital admission for another reason. Overall, 190 (52.1%) had a known history of epilepsy and 254 (70.0%) presented with SE with prominent motor activity. The mean Status Epilepticus Severity Score (STESS) was 2.15 and the mean SE duration of all patients was 44 min. SE self‐terminated without any treatment in 84 patients (22.7%). Earlier administration of appropriately dosed benzodiazepine in the pre‐hospital setting was a major determinant of SE duration. Univariate analysis demonstrated that mortality was significantly higher in older patients, patients with longer durations of SE, higher STESS, and patients who developed SE in hospital, but these did not maintain significance with multivariate analysis. There was no difference in the performance of the health care system in the treatment of SE across ethnic groups.
Significance
When SE was defined as 10 continuous minutes of seizure, overall mortality was lower than expected and many patients had self‐limited presentations for which no treatment was required. Although there were disparities in the incidence of SE across ethnic groups there was no difference in treatment or outcome. The finding highlights the benefit of a health care system designed to deliver universal health care. Abstract Objective Determination of the real‐world performance of a health care system in the treatment of status epilepticus (SE). Methods Prospective, multicenter population‐based study of SE in Auckland, New Zealand (NZ) over 1 year, with data recorded in the EpiNet database. Focus on treatment patterns and determinants of SE duration and 30‐day mortality. The incidence, etiology, ethnic discrepancies, and seizure characteristics of this cohort have been published previously. Results A total of 365 patients were included in this treatment cohort; 326 patients (89.3%) were brought to hospital because of SE, whereas 39 patients (10.7%) developed SE during a hospital admission for another reason. Overall, 190 (52.1%) had a known history of epilepsy and 254 (70.0%) presented with SE with prominent motor activity. The mean Status Epilepticus Severity Score (STESS) was 2.15 and the mean SE duration of all patients was 44 min. SE self‐terminated without any treatment in 84 patients (22.7%). Earlier administration of appropriately dosed benzodiazepine in the pre‐hospital setting was a major determinant of SE duration. Univariate analysis demonstrated that mortality was significantly higher in older patients, patients with longer durations of SE, higher STESS, and patients who developed SE in hospital, but these did not maintain significance with multivariate analysis. There was no difference in the performance of the health care system in the treatment of SE across ethnic groups. Significance When SE was defined as 10 continuous minutes of seizure, overall mortality was lower than expected and many patients had self‐limited presentations for which no treatment was required. Although there were disparities in the incidence of SE across ethnic groups there was no difference in treatment or outcome. The finding highlights the benefit of a health care system designed to deliver universal health care. ObjectiveDetermination of the real‐world performance of a health care system in the treatment of status epilepticus (SE).MethodsProspective, multicenter population‐based study of SE in Auckland, New Zealand (NZ) over 1 year, with data recorded in the EpiNet database. Focus on treatment patterns and determinants of SE duration and 30‐day mortality. The incidence, etiology, ethnic discrepancies, and seizure characteristics of this cohort have been published previously.ResultsA total of 365 patients were included in this treatment cohort; 326 patients (89.3%) were brought to hospital because of SE, whereas 39 patients (10.7%) developed SE during a hospital admission for another reason. Overall, 190 (52.1%) had a known history of epilepsy and 254 (70.0%) presented with SE with prominent motor activity. The mean Status Epilepticus Severity Score (STESS) was 2.15 and the mean SE duration of all patients was 44 min. SE self‐terminated without any treatment in 84 patients (22.7%). Earlier administration of appropriately dosed benzodiazepine in the pre‐hospital setting was a major determinant of SE duration. Univariate analysis demonstrated that mortality was significantly higher in older patients, patients with longer durations of SE, higher STESS, and patients who developed SE in hospital, but these did not maintain significance with multivariate analysis. There was no difference in the performance of the health care system in the treatment of SE across ethnic groups.SignificanceWhen SE was defined as 10 continuous minutes of seizure, overall mortality was lower than expected and many patients had self‐limited presentations for which no treatment was required. Although there were disparities in the incidence of SE across ethnic groups there was no difference in treatment or outcome. The finding highlights the benefit of a health care system designed to deliver universal health care. Determination of the real-world performance of a health care system in the treatment of status epilepticus (SE). Prospective, multicenter population-based study of SE in Auckland, New Zealand (NZ) over 1 year, with data recorded in the EpiNet database. Focus on treatment patterns and determinants of SE duration and 30-day mortality. The incidence, etiology, ethnic discrepancies, and seizure characteristics of this cohort have been published previously. A total of 365 patients were included in this treatment cohort; 326 patients (89.3%) were brought to hospital because of SE, whereas 39 patients (10.7%) developed SE during a hospital admission for another reason. Overall, 190 (52.1%) had a known history of epilepsy and 254 (70.0%) presented with SE with prominent motor activity. The mean Status Epilepticus Severity Score (STESS) was 2.15 and the mean SE duration of all patients was 44 min. SE self-terminated without any treatment in 84 patients (22.7%). Earlier administration of appropriately dosed benzodiazepine in the pre-hospital setting was a major determinant of SE duration. Univariate analysis demonstrated that mortality was significantly higher in older patients, patients with longer durations of SE, higher STESS, and patients who developed SE in hospital, but these did not maintain significance with multivariate analysis. There was no difference in the performance of the health care system in the treatment of SE across ethnic groups. When SE was defined as 10 continuous minutes of seizure, overall mortality was lower than expected and many patients had self-limited presentations for which no treatment was required. Although there were disparities in the incidence of SE across ethnic groups there was no difference in treatment or outcome. The finding highlights the benefit of a health care system designed to deliver universal health care. |
Author | Thornton, Vanessa Jayabal, Jayaganth Litchfield, Rhonda Scott, Shona Zhang, Tony Beilharz, Erica Yates, Kim Dalziel, Stuart R. Brockington, Alice Stephens, Eleanor Jones, Peter Fong, Michael W. K. Bergin, Peter S. |
Author_xml | – sequence: 1 givenname: Michael W. K. orcidid: 0000-0002-5666-5234 surname: Fong fullname: Fong, Michael W. K. organization: Yale University School of Medicine – sequence: 2 givenname: Eleanor surname: Stephens fullname: Stephens, Eleanor organization: University of Sydney – sequence: 3 givenname: Alice surname: Brockington fullname: Brockington, Alice organization: Sheffield Teaching Hospitals, NHS Foundation Trust – sequence: 4 givenname: Jayaganth surname: Jayabal fullname: Jayabal, Jayaganth organization: Pantai‐Gleneagles Hospital – sequence: 5 givenname: Shona surname: Scott fullname: Scott, Shona organization: Western General Hospital – sequence: 6 givenname: Tony orcidid: 0000-0001-5670-6537 surname: Zhang fullname: Zhang, Tony organization: Auckland District Health Board, Grafton – sequence: 7 givenname: Rhonda surname: Litchfield fullname: Litchfield, Rhonda organization: Auckland District Health Board, Grafton – sequence: 8 givenname: Erica surname: Beilharz fullname: Beilharz, Erica organization: Auckland District Health Board, Grafton – sequence: 9 givenname: Stuart R. surname: Dalziel fullname: Dalziel, Stuart R. organization: University of Auckland – sequence: 10 givenname: Peter surname: Jones fullname: Jones, Peter organization: Auckland District Health Board, Grafton – sequence: 11 givenname: Kim surname: Yates fullname: Yates, Kim organization: Waitematā District Health Board – sequence: 12 givenname: Vanessa surname: Thornton fullname: Thornton, Vanessa organization: Counties Manukau District Health Board – sequence: 13 givenname: Peter S. orcidid: 0000-0003-0181-1959 surname: Bergin fullname: Bergin, Peter S. email: pbergin@adhb.govt.nz organization: Centre for Brain Research, University of Auckland |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38634858$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kcFu1DAQhq2qqN0WDn0BZIkLSKS148R2uFVVgUoVrcSeuEQTZ6KmTew0dqh648SZZ-RJmGULByR88dj69Glm_gO264NHxo6kOJZ0TnDqj6WpTLnDVrLMbSalNrtsJYRUWVVasc8OYrwVQhht1B7bV1arwpZ2xb5_TpCWyEkx4JR6R3Xv-eni7gbw7Vv-CR_4F4TN4x1fzwhpRJ_4BCnh7COnf94i1WPvwafIQ8fDklwYcSMCPs0hTuhS_xX5FKZlgNQH__PbjwYittyFmzCn5-xZB0PEF0_3IVu_P1-ffcwurz5cnJ1eZm7Tb9aUuoWuEEaC07qspCqgUaIsVKVzY3MrG91VuWhpC4hSFq0toCSqgU4WoA7Z662WmrpfMKZ67KPDgabDsMRaiULmSlRGE_rqH_Q2LLOn5ojSWlmTVxVRb7aUoynjjF09zf0I82MtRb3JpqbF1r-zIfblk3FpRmz_kn_CIOBkCzxQFo__N9Xn1xdb5S9ExZvu |
Cites_doi | 10.1136/jnnp-2021-326443 10.1111/j.1528-1167.2011.03235.x 10.1111/epi.14478 10.1007/s00415-008-0989-1 10.1111/j.1528-1167.2009.02188.x 10.1007/s00415-015-7992-0 10.1016/S0140-6736(20)30611-5 10.1093/brain/awu042 10.1001/jamaneurol.2017.4382 10.1056/NEJMoa2115998 10.1212/WNL.0000000000000082 10.1212/WNL.58.1.139 10.1002/ana.24697 10.1016/S0140-6736(19)30722-6 10.1016/S0140-6736(19)30724-X 10.1016/S1474-4422(16)30137-5 10.1111/epi.13056 10.1097/WNP.0000000000000806 10.1007/s00134-015-3834-x 10.1111/epi.16277 10.1212/WNL.58.7.1070 10.1212/CPJ.0000000000200101 10.1056/NEJMoa1905795 10.5698/1535-7597-16.1.48 10.1016/j.seizure.2022.02.012 |
ContentType | Journal Article |
Copyright | 2024 The Authors. published by Wiley Periodicals LLC on behalf of International League Against Epilepsy. 2024 The Authors. Epilepsia published by Wiley Periodicals LLC on behalf of International League Against Epilepsy. 2024. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: 2024 The Authors. published by Wiley Periodicals LLC on behalf of International League Against Epilepsy. – notice: 2024 The Authors. Epilepsia published by Wiley Periodicals LLC on behalf of International League Against Epilepsy. – notice: 2024. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | 24P WIN NPM AAYXX CITATION 7TK 7X8 |
DOI | 10.1111/epi.17975 |
DatabaseName | Wiley Online Library Open Access Wiley Online Library Free Content PubMed CrossRef Neurosciences Abstracts MEDLINE - Academic |
DatabaseTitle | PubMed CrossRef Neurosciences Abstracts MEDLINE - Academic |
DatabaseTitleList | CrossRef Neurosciences Abstracts PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1528-1167 |
EndPage | 1619 |
ExternalDocumentID | 10_1111_epi_17975 38634858 EPI17975 |
Genre | researchArticle Journal Article |
GeographicLocations | New Zealand |
GeographicLocations_xml | – name: New Zealand |
GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1OB 1OC 24P 29G 2WC 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAGKA AAHHS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABEML ABIVO ABJNI ABLJU ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFO ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFZJQ AHBTC AHEFC AI. AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BAWUL BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EBS EJD EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FIJ FUBAC FYBCS G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IPNFZ IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OHT OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PALCI Q.N Q11 QB0 R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ TEORI TR2 UB1 V8K V9Y VH1 W8V W99 WBKPD WHWMO WIH WIJ WIK WIN WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR X7M XG1 YFH YOC YUY ZGI ZXP ZZTAW ~IA ~WT NPM AAYXX CITATION 7TK 7X8 |
ID | FETCH-LOGICAL-c3485-b56daf4071ac6659134ab3054396278281b6f920d152ee114d84a5134baf14a3 |
IEDL.DBID | DR2 |
ISSN | 0013-9580 |
IngestDate | Sat Oct 26 04:57:33 EDT 2024 Thu Oct 10 16:56:33 EDT 2024 Fri Aug 23 03:16:35 EDT 2024 Sat Nov 02 12:30:01 EDT 2024 Sat Aug 24 00:58:08 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Keywords | anti‐seizure medication status epilepticus status epilepticus outcomes status epilepticus treatment |
Language | English |
License | Attribution-NonCommercial 2024 The Authors. Epilepsia published by Wiley Periodicals LLC on behalf of International League Against Epilepsy. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3485-b56daf4071ac6659134ab3054396278281b6f920d152ee114d84a5134baf14a3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-5666-5234 0000-0003-0181-1959 0000-0001-5670-6537 |
OpenAccessLink | https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fepi.17975 |
PMID | 38634858 |
PQID | 3066387299 |
PQPubID | 1066359 |
PageCount | 15 |
ParticipantIDs | proquest_miscellaneous_3041230976 proquest_journals_3066387299 crossref_primary_10_1111_epi_17975 pubmed_primary_38634858 wiley_primary_10_1111_epi_17975_EPI17975 |
PublicationCentury | 2000 |
PublicationDate | June 2024 |
PublicationDateYYYYMMDD | 2024-06-01 |
PublicationDate_xml | – month: 06 year: 2024 text: June 2024 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Hoboken |
PublicationTitle | Epilepsia (Copenhagen) |
PublicationTitleAlternate | Epilepsia |
PublicationYear | 2024 |
Publisher | Wiley Subscription Services, Inc |
Publisher_xml | – name: Wiley Subscription Services, Inc |
References | 2015; 56 2002; 58 2023; 13 2011; 52 2007 2016; 16 2019; 381 2016; 15 2014; 82 2016; 263 2014; 137 2021; 92 2022; 386 2021; 38 2019; 60 2020; 395 2015; 41 2018 2022; 97 2016; 80 2019; 393 2008; 255 2018; 75 2018; 59 2010; 51 e_1_2_11_10_1 e_1_2_11_14_1 e_1_2_11_13_1 PHARMAC (e_1_2_11_23_1) 2018 e_1_2_11_12_1 e_1_2_11_11_1 e_1_2_11_7_1 e_1_2_11_6_1 e_1_2_11_28_1 e_1_2_11_5_1 e_1_2_11_27_1 e_1_2_11_4_1 e_1_2_11_26_1 e_1_2_11_3_1 e_1_2_11_2_1 e_1_2_11_21_1 e_1_2_11_20_1 e_1_2_11_25_1 e_1_2_11_24_1 e_1_2_11_9_1 e_1_2_11_8_1 e_1_2_11_22_1 e_1_2_11_18_1 e_1_2_11_17_1 e_1_2_11_16_1 e_1_2_11_15_1 e_1_2_11_19_1 |
References_xml | – volume: 60 start-page: 1552 issue: 8 year: 2019 end-page: 1564 article-title: Status epilepticus in Auckland, New Zealand: incidence, etiology, and outcomes publication-title: Epilepsia – volume: 82 start-page: 396 issue: 5 year: 2014 end-page: 404 article-title: Electrographic status epilepticus and long‐term outcome in critically ill children publication-title: Neurology – volume: 92 start-page: 1341 issue: 12 year: 2021 end-page: 1345 article-title: Misdiagnosis of prolonged psychogenic non‐epileptic seizures as status epilepticus: epidemiology and associated risks publication-title: J Neurol Neurosurg Psychiatry – volume: 15 start-page: 1054 issue: 10 year: 2016 end-page: 1062 article-title: Diagnostic accuracy of the Salzburg EEG criteria for non‐convulsive status epilepticus: a retrospective study publication-title: Lancet Neurol – volume: 52 start-page: 45 issue: Suppl 8 year: 2011 end-page: 47 article-title: Neurological emergency treatment trials I. RAMPART (rapid anticonvulsant medication prior to arrival trial): a double‐blind randomized clinical trial of the efficacy of intramuscular midazolam versus intravenous lorazepam in the prehospital treatment of status epilepticus by paramedics publication-title: Epilepsia – year: 2007 – volume: 393 start-page: 2135 issue: 10186 year: 2019 end-page: 2145 article-title: Levetiracetam versus phenytoin for second‐line treatment of convulsive status epilepticus in children (ConSEPT): an open‐label, multicentre, randomised controlled trial publication-title: Lancet – volume: 255 start-page: 1561 issue: 10 year: 2008 end-page: 1566 article-title: Status epilepticus severity score (STESS): a tool to orient early treatment strategy publication-title: J Neurol – volume: 386 start-page: 724 issue: 8 year: 2022 end-page: 734 article-title: Treating rhythmic and periodic EEG patterns in comatose survivors of cardiac arrest publication-title: N Engl J Med – volume: 137 start-page: 1429 issue: Pt 5 year: 2014 end-page: 1438 article-title: Seizure burden is independently associated with short term outcome in critically ill children publication-title: Brain – volume: 38 start-page: 1 issue: 1 year: 2021 end-page: 29 article-title: American clinical neurophysiology Society's standardized critical care EEG terminology: 2021 version publication-title: J Clin Neurophysiol – volume: 51 start-page: 57 issue: 1 year: 2010 end-page: 61 article-title: Long‐term survival in patients with status epilepticus: a tertiary referral center study publication-title: Epilepsia – volume: 381 start-page: 2103 issue: 22 year: 2019 end-page: 2113 article-title: Randomized trial of three anticonvulsant medications for status epilepticus publication-title: N Engl J Med – year: 2018 – volume: 80 start-page: 175 issue: 2 year: 2016 end-page: 184 article-title: Clinically distinct electroencephalographic phenotypes of early myoclonus after cardiac arrest publication-title: Ann Neurol – volume: 97 start-page: 1 year: 2022 end-page: 7 article-title: Recurrent status epilepticus: clinical features and recurrence risk in an adult population publication-title: Seizure – volume: 59 start-page: 144 year: 2018 end-page: 149 article-title: EpiNet study of incidence of status epilepticus in Auckland, New Zealand: methods and preliminary results publication-title: Epilepsia – volume: 58 start-page: 1070 issue: 7 year: 2002 end-page: 1076 article-title: Incidence and mortality of generalized convulsive status epilepticus in California publication-title: Neurology – volume: 393 start-page: 2125 issue: 10186 year: 2019 end-page: 2134 article-title: Levetiracetam versus phenytoin for second‐line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open‐label, randomised trial publication-title: Lancet – volume: 395 start-page: 1217 issue: 10231 year: 2020 end-page: 1224 article-title: Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double‐blind, responsive‐adaptive, randomised controlled trial publication-title: Lancet – volume: 41 start-page: 1264 issue: 7 year: 2015 end-page: 1272 article-title: Prognostication of post‐cardiac arrest coma: early clinical and electroencephalographic predictors of outcome publication-title: Intensive Care Med – volume: 58 start-page: 139 issue: 1 year: 2002 end-page: 142 article-title: Predictors of functional disability and mortality after status epilepticus publication-title: Neurology – volume: 75 start-page: 410 issue: 4 year: 2018 end-page: 418 article-title: Association of Time to treatment with Short‐term outcomes for pediatric patients with refractory convulsive status epilepticus publication-title: JAMA Neurol – volume: 16 start-page: 48 issue: 1 year: 2016 end-page: 61 article-title: Evidence‐based guideline: treatment of convulsive status epilepticus in children and adults: report of the guideline Committee of the American Epilepsy Society publication-title: Epilepsy Curr – volume: 263 start-page: 485 issue: 3 year: 2016 end-page: 491 article-title: Association of seizure duration and outcome in refractory status epilepticus publication-title: J Neurol – volume: 56 start-page: 1275 issue: 8 year: 2015 end-page: 1285 article-title: Practice variability and efficacy of clonazepam, lorazepam, and midazolam in status epilepticus: a multicenter comparison publication-title: Epilepsia – volume: 13 issue: 1 year: 2023 article-title: Racial and ethnic differences in Antiseizure medications among people with epilepsy on Medicaid: a case of potential inequities publication-title: Neurol Clin Pract – ident: e_1_2_11_20_1 doi: 10.1136/jnnp-2021-326443 – ident: e_1_2_11_3_1 doi: 10.1111/j.1528-1167.2011.03235.x – ident: e_1_2_11_10_1 doi: 10.1111/epi.14478 – ident: e_1_2_11_13_1 doi: 10.1007/s00415-008-0989-1 – ident: e_1_2_11_16_1 doi: 10.1111/j.1528-1167.2009.02188.x – ident: e_1_2_11_25_1 doi: 10.1007/s00415-015-7992-0 – ident: e_1_2_11_8_1 doi: 10.1016/S0140-6736(20)30611-5 – ident: e_1_2_11_27_1 doi: 10.1093/brain/awu042 – ident: e_1_2_11_6_1 doi: 10.1001/jamaneurol.2017.4382 – ident: e_1_2_11_26_1 doi: 10.1056/NEJMoa2115998 – ident: e_1_2_11_28_1 doi: 10.1212/WNL.0000000000000082 – ident: e_1_2_11_15_1 doi: 10.1212/WNL.58.1.139 – volume-title: Variation in medicines use by ethnicity: a comparison between 2006/7 and 2012/13 year: 2018 ident: e_1_2_11_23_1 contributor: fullname: PHARMAC – ident: e_1_2_11_19_1 doi: 10.1002/ana.24697 – ident: e_1_2_11_9_1 doi: 10.1016/S0140-6736(19)30722-6 – ident: e_1_2_11_5_1 doi: 10.1016/S0140-6736(19)30724-X – ident: e_1_2_11_12_1 doi: 10.1016/S1474-4422(16)30137-5 – ident: e_1_2_11_4_1 doi: 10.1111/epi.13056 – ident: e_1_2_11_11_1 doi: 10.1097/WNP.0000000000000806 – ident: e_1_2_11_18_1 doi: 10.1007/s00134-015-3834-x – ident: e_1_2_11_2_1 doi: 10.1111/epi.16277 – ident: e_1_2_11_17_1 doi: 10.1212/WNL.58.7.1070 – ident: e_1_2_11_24_1 doi: 10.1212/CPJ.0000000000200101 – ident: e_1_2_11_7_1 doi: 10.1056/NEJMoa1905795 – ident: e_1_2_11_14_1 doi: 10.5698/1535-7597-16.1.48 – ident: e_1_2_11_21_1 doi: 10.1016/j.seizure.2022.02.012 – ident: e_1_2_11_22_1 |
SSID | ssj0007673 |
Score | 2.49185 |
Snippet | Objective
Determination of the real‐world performance of a health care system in the treatment of status epilepticus (SE).
Methods
Prospective, multicenter... Determination of the real-world performance of a health care system in the treatment of status epilepticus (SE). Prospective, multicenter population-based... Abstract Objective Determination of the real‐world performance of a health care system in the treatment of status epilepticus (SE). Methods Prospective,... ObjectiveDetermination of the real‐world performance of a health care system in the treatment of status epilepticus (SE).MethodsProspective, multicenter... OBJECTIVEDetermination of the real-world performance of a health care system in the treatment of status epilepticus (SE).METHODSProspective, multicenter... |
SourceID | proquest crossref pubmed wiley |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 1605 |
SubjectTerms | anti‐seizure medication Benzodiazepines Convulsions & seizures Epilepsy Health care Minority & ethnic groups Mortality Motor activity Multivariate analysis Patients Population studies Seizures status epilepticus status epilepticus outcomes status epilepticus treatment |
Title | Status epilepticus in Auckland, New Zealand: Treatment patterns and determinants of outcome in a prospective population‐based cohort |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fepi.17975 https://www.ncbi.nlm.nih.gov/pubmed/38634858 https://www.proquest.com/docview/3066387299 https://www.proquest.com/docview/3041230976 |
Volume | 65 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1JT90wEB5RDlUvBbqGTS7qgUPzlBcvidsTYhFFokLoVeJQKbJjR0JUeU-85MKJE2d-I7-EmWyFIqSqNyux423G801mMcBnabWWcSLD1AgZCu5FaMj-7mNlc6tzb5so1-Mf6vCnODqTZwvwrY-FafNDDD_ciDOa85oY3Nj5Ayb3s_MRUlNCAeZjnpA7197pn9RRieqsy2MeaplGXVYh8uIZWj6WRU8A5mO82gicgyX41Q-19TO5GNWVHeVXf2Vx_M-5LMPrDoiynZZyVmDBl2_g5XFnan8LNwRD6znDRr_J8yXH8nnJdsgWbEr3heHxyDrPyK9s0vurs1mTsLOcM3zO3ANnGzYt2LSucGiePmQYzqyP82Sz4R6xu-tbkqyO0dW9l9U7mBzsT3YPw-7ShjDnIpWhlcqZgtREkyslybBvLB4qCHxUjHAEYbIqdBw5BA7eozbmUmEk1rKmGAvD38NiOS39R2C64C4yzmpfJMJF2hjPc4GSVsSIuYpxAFv97mWzNjVH1qs0uDZZs6ABrPf7mnXcOc844awU1QodwKfhNfIVGUtM6ac11aGuIkRrAXxo6WHohaeK5poGsN3s6vPdZ_sn35vC6r9XXYNXMSKn1h9tHRary9pvIPKp7Ca8iMXJZkPo96kNATY |
link.rule.ids | 315,783,787,1378,11574,27936,27937,46064,46306,46488,46730 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1LS8QwEB58gHoR39ZnFA8erHTbJNuIFxFlfax4WMFbSZoUFqS7uLt3T579jf4SZ_pCEcFbaNNOO4_Ml8xkAnAkjFIibAs_1lz4PHLc1xR_d6E0qVGpM8Uu1-6D7Dzx22fxPAXn9V6Ysj5Es-BGllGM12TgtCD9zcrdsH-K6tQW0zDLJSoi1XXmj8043JZVfLkV-UrEQVVXiPJ4mkd_eqNfEPMnYi1czvUSLFZYkV2Uwl2GKZevwFy3ioavwjshxcmIIZ0XSk5Jsd3P2QWFa3VuTxiOYKxKXjxjvTqlnA2Lmpr5iOF1Zr_lw7BBxgaTMXLC0Ys0w0-tt2KyYXPU1-fbBzk_y-h03dfxGvSur3qXHb86V8FPIx4L3whpdUYzOZ1KKSj2rg3aPWITGSJiQCQrMxUGFn27czhhsjHXAnsZnbW4jtZhJh_kbhOYyiIbaGuUy9rcBkprF6UcnSEPERZlLQ8Oa_Ymw7J6RlLPOpA3SSEDD3ZqxieVAY2SiKBQjMhfeXDQ3EbVp3iGzt1gQn2IVICAyoONUmANlSiW9K-xB8eFBP8mn1w93hSNrf933Yf5Tq97n9zfPNxtw0KIQKdMH9uBmfHrxO0iUBmbvUIfvwDIe-Ox |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB5RKqFegL4gQMGteuDQrLKJ7Y3LCRVW0AJC1VbiUCmyY0dagbIRm1x66qnn_kZ-SWfy4lFVqrhZiR177BnPN5nxGOC9MEqJcCT8WHPh88hxX5P_3YXSpEalztSnXE_P5NE3_vlCXCzAXncWpskP0f9wI8mo92sS8MJmd4TcFdMBctNIPIGnXCLyJUT09TZ31Ei27uVh5CsRB21aIQrj6ZveV0Z_Icz7gLXWOOMV-N6NtQk0uRxUpRmkPx6kcXwkMauw3CJRtt-wznNYcPkLWDptfe0v4Rfh0GrOsNEVhb6kWJ7mbJ-cwTq3Hxjuj6wNjfzIJl3AOivqjJ35nOFzZu9E27BZxmZViUNz9CHNkLLuoCcr-ovEbn7-JtVqGd3de12-gsn4cPLpyG9vbfDTiMfCN0JanZGdqFMpBXn2tcFdBZGPDBGPIE6WmQoDi8jBOTTHbMy1wFpGZ0Ouo9ewmM9ytw5MZZENtDXKZSNuA6W1i1KOqpaHCLqyoQfvutVLiiY3R9LZNDg3ST2hHmx165q04jlPIgJaMdoVyoO3_WsULPKW6NzNKqpDXQUI1zxYa_ih7yWKJdEae7Bbr-q_u08Oz4_rwsb_V92BpfODcXJyfPZlE56FiKKa2LQtWCyvK_cGUVBptmtu_wOKAgMm |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Status+epilepticus+in+Auckland%2C+New+Zealand%3A+Treatment+patterns+and+determinants+of+outcome+in+a+prospective+population%E2%80%90based+cohort&rft.jtitle=Epilepsia+%28Copenhagen%29&rft.au=Fong%2C+Michael+W.+K.&rft.au=Stephens%2C+Eleanor&rft.au=Brockington%2C+Alice&rft.au=Jayabal%2C+Jayaganth&rft.date=2024-06-01&rft.issn=0013-9580&rft.eissn=1528-1167&rft.volume=65&rft.issue=6&rft.spage=1605&rft.epage=1619&rft_id=info:doi/10.1111%2Fepi.17975&rft.externalDBID=10.1111%252Fepi.17975&rft.externalDocID=EPI17975 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0013-9580&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0013-9580&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0013-9580&client=summon |